These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 28131770)

  • 21. KDI tripeptide of gamma1 laminin protects rat dopaminergic neurons from 6-OHDA induced toxicity.
    Väänänen AJ; Rauhala P; Tuominen RK; Liesi P
    J Neurosci Res; 2006 Aug; 84(3):655-65. PubMed ID: 16810683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation.
    Etievant A; Bétry C; Arnt J; Haddjeri N
    Neurosci Lett; 2009 Aug; 460(1):82-6. PubMed ID: 19450663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protective effects of ethanolic extract of Delphinium denudatum in a rat model of Parkinson's disease.
    Ahmad M; Yousuf S; Khan MB; Ahmad AS; Saleem S; Hoda MN; Islam F
    Hum Exp Toxicol; 2006 Jul; 25(7):361-8. PubMed ID: 16898164
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intrastriatal infusion of lisuride--a potential treatment for Parkinson's disease? Behavioral and autoradiographic studies in 6-OHDA lesioned rats.
    May CH; Guilarte TR; Wagner HN; Vogel S
    Neurodegeneration; 1994 Dec; 3(4):305-13. PubMed ID: 7842301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The high-affinity D2/D3 agonist D512 protects PC12 cells from 6-OHDA-induced apoptotic cell death and rescues dopaminergic neurons in the MPTP mouse model of Parkinson's disease.
    Shah M; Rajagopalan S; Xu L; Voshavar C; Shurubor Y; Beal F; Andersen JK; Dutta AK
    J Neurochem; 2014 Oct; 131(1):74-85. PubMed ID: 24848702
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons.
    Du F; Li R; Huang Y; Li X; Le W
    Eur J Neurosci; 2005 Nov; 22(10):2422-30. PubMed ID: 16307585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discriminative stimulus properties of lisuride revisited: involvement of dopamine D2 receptors.
    Cunningham KA; Callahan PM; Appel JB
    J Pharmacol Exp Ther; 1987 Apr; 241(1):147-51. PubMed ID: 3553537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences.
    Ahmad M; Saleem S; Ahmad AS; Yousuf S; Ansari MA; Khan MB; Ishrat T; Chaturvedi RK; Agrawal AK; Islam F
    J Neurochem; 2005 Apr; 93(1):94-104. PubMed ID: 15773909
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic effect of galantamine on nicotine-induced neuroprotection in hemiparkinsonian rat model.
    Yanagida T; Takeuchi H; Kitamura Y; Takata K; Minamino H; Shibaike T; Tsushima J; Kishimoto K; Yasui H; Taniguchi T; Shimohama S
    Neurosci Res; 2008 Dec; 62(4):254-61. PubMed ID: 18845194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
    Liu H; Jia L; Chen X; Shi L; Xie J
    Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
    J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estrogen interacts with the IGF-1 system to protect nigrostriatal dopamine and maintain motoric behavior after 6-hydroxdopamine lesions.
    Quesada A; Micevych PE
    J Neurosci Res; 2004 Jan; 75(1):107-16. PubMed ID: 14689453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats.
    Pang Y; Lin S; Wright C; Shen J; Carter K; Bhatt A; Fan LW
    Neuroscience; 2016 Mar; 318():157-65. PubMed ID: 26777890
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spinal cord dopamine receptor expression and function in mice with 6-OHDA lesion of the A11 nucleus and dietary iron deprivation.
    Zhao H; Zhu W; Pan T; Xie W; Zhang A; Ondo WG; Le W
    J Neurosci Res; 2007 Apr; 85(5):1065-76. PubMed ID: 17342757
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist.
    Glennon JC; Van Scharrenburg G; Ronken E; Hesselink MB; Reinders JH; Van Der Neut M; Long SK; Feenstra RW; McCreary AC
    Synapse; 2006 Dec; 60(8):599-608. PubMed ID: 17001660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protective and restorative effects of magnolol on neurotoxicity in mice with 6-hydroxydopamine-induced hemiparkinsonism.
    Chen HH; Lin SC; Chan MH
    Neurodegener Dis; 2011; 8(5):364-74. PubMed ID: 21494012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions.
    Machado-Filho JA; Correia AO; Montenegro AB; Nobre ME; Cerqueira GS; Neves KR; Naffah-Mazzacoratti Mda G; Cavalheiro EA; de Castro Brito GA; de Barros Viana GS
    Behav Brain Res; 2014 May; 264():116-25. PubMed ID: 24525422
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Altered expression of dopamine receptors in cholinergic motoneurons of the hypoglossal nucleus in a 6-OHDA-induced Parkinson's disease rat model.
    Zhou L; Wang ZY; Lian H; Song HY; Zhang YM; Zhang XL; Fan RF; Zheng LF; Zhu JX
    Biochem Biophys Res Commun; 2014 Sep; 452(3):560-6. PubMed ID: 25172664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease.
    Ryoo HL; Pierrotti D; Joyce JN
    Mov Disord; 1998 Sep; 13(5):788-97. PubMed ID: 9756147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.